

# SEQUENCE LISTING

<110> Life Sciences Research Partners VZW  
 Saint-Remy, Jean-Marie

<120> Strategies to prevent and/or treat immune responses to soluble  
 allofactors

<130> T5212-PCT (043)

<150> EP 08447010.3  
 <151> 2008-02-14

<150> US 61/035,800  
 <151> 2008-03-12

<160> 16

<170> PatentIn version 3.3

<210> 1  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> T-cell epitope of CDR3 of anti-factor VIII antibody B02C11

<400> 1

Tyr Cys Ala Val Pro Asp Asp Pro Asp Ala  
 1 5 10

<210> 2  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> modified T-cell epitope of CDR3 of anti-factor VIII antibody  
 B02C11

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(4)  
 <223> thioreductase motif

<400> 2

Cys His Gly Cys Tyr Cys Ala Val Pro Asp Pro Asp Ala  
 1 5 10

<210> 3  
 <211> 18  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> amino acids 2144-2161 of human factor VIII

<400> 3

Ile Ile Ala Arg Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg  
1 5 10 15

Ser Thr

<210> 4

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> modified T-cell epitope of human factor VIII

<220>

<221> MISC\_FEATURE

<222> (1)..(4)

<223> thioreductase motif

<220>

<221> MISC\_FEATURE

<222> (5)..(6)

<223> Gly-Gly linker

<400> 4

Cys Gly His Cys Gly Gly Ile Arg Leu His Pro Thr His Tyr Ser Ile  
1 5 10 15

Arg

<210> 5

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> modified human factor VIII T-cell epitope

<220>

<221> MISC\_FEATURE

<222> (1)..(4)

<223> thioreductase motif

<220>

<221> MISC\_FEATURE

<222> (5)..(6)

<223> Gly-Gly-linker

<400> 5

Cys Gly His Cys Gly Gly Phe Thr Asn Met Phe Ala Thr Trp Ser Pro  
1 5 10 15

Ser Lys

<210> 6  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> general sequence of peptide of the invention

<220>  
<221> MISC\_FEATURE  
<222> (2)..(3)  
<223> Xaa at positions 2 and 3 denote any amino acid

<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> Xaa denotes the sequence of any T-cell epitope

<400> 6

Cys Xaa Xaa Cys Gly Xaa  
1 5

<210> 7  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> general sequence of peptide of the invention

<220>  
<221> MISC\_FEATURE  
<222> (2)..(3)  
<223> Xaa at positions 2 and 3 denote any amino acid

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Xaa denotes sequence of any T-cell epitope

<400> 7

Cys Xaa Xaa Cys Gly Gly Xaa  
1 5

<210> 8  
<211> 8

<212> PRT  
<213> Artificial Sequence

<220>  
<223> general sequence of peptide of the invention

<220>  
<221> MISC\_FEATURE  
<222> (2)..(3)  
<223> Xaa at positions 2 and 3 denote any amino acid

<220>  
<221> MISC\_FEATURE  
<222> (8)..(8)  
<223> Xaa denotes sequence of any T-cell epitope

<400> 8

Cys Xaa Xaa Cys Ser Ser Ser Xaa  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> general sequence of peptide of the invention

<220>  
<221> MISC\_FEATURE  
<222> (2)..(3)  
<223> Xaa at positions 2 and 3 denote any amino acid

<220>  
<221> MISC\_FEATURE  
<222> (9)..(9)  
<223> Xaa denotes sequence of any T-cell epitope

<400> 9

Cys Xaa Xaa Cys Ser Gly Ser Gly Xaa  
1 5

<210> 10  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> thioreductase motif repeat

<220>  
<221> MISC\_FEATURE  
<222> (1)..(14)  
<223> Xaa at positions 2, 3, 5, 7, 8, 10, 12, and 13 denote any amino

acid

<400> 10

Cys Xaa Xaa Cys Xaa Cys Xaa Xaa Cys Xaa Cys Xaa Xaa Cys  
1 5 10

<210> 11

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> thioreductase motif repeat

<220>

<221> MISC\_FEATURE

<222> (1)..(12)

<223> Xaa at positions 2, 3, 6, 7, 10, and 11 denote any amino acid

<400> 11

Cys Xaa Xaa Cys Cys Xaa Xaa Cys Cys Xaa Xaa Cys  
1 5 10

<210> 12

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> thioreductase motif repeat

<220>

<221> MISC\_FEATURE

<222> (1)..(10)

<223> Xaa at positions 2, 3, 5, 6, 8, and 9 denote any amino acid

<400> 12

Cys Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Cys  
1 5 10

<210> 13

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> thioreductase motif repeat

<220>

<221> MISC\_FEATURE

<222> (1)..(10)

<223> Xaa at positions 2, 5, and 8 denote any amino acid

<400> 13

Cys Xaa Cys Cys Xaa Cys Cys Xaa Cys Cys  
1 5 10

<210> 14

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> late endosome targeting signal

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa denotes aspartate (D or Asp) or glutamate (E or Glu)

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at positions 2, 3 and 4 denote any amino acid

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa denotes leucine (L or Leu) or isoleucine (I or Ile)

<400> 14

Xaa Xaa Xaa Xaa Leu Xaa  
1 5

<210> 15

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> late endosome targeting signal

<220>

<221> MISC\_FEATURE

<222> (2)..(3)

<223> Xaa at positions 2 and 3 denote any amino acid

<400> 15

Asp Xaa Xaa Leu Leu  
1 5

<210> 16

<211> 6

<212> PRT

<213> Artificial Sequence

<220>  
<223> late endosome targeting signal

<220>  
<221> MISC\_FEATURE  
<222> (2)..(5)  
<223> Xaa at positions 2, 3 and 4 denote any amino acid

<400> 16

Asp Xaa Xaa Xaa Leu Leu  
1 5